You're staring at a USMLE practice question. Or maybe a shelf exam. Or you're a third-year medical student on your heme/onc rotation, and the attending just asked you to rattle off the differential for an elevated hematocrit — and you froze Simple, but easy to overlook. Took long enough..
We've all been there Most people skip this — try not to..
The question usually looks something like this: A 62-year-old man presents with headache, dizziness, and ruddy complexion. Labs show Hb 19.2, Hct 58%. Which of the following would NOT lead to polycythemia? Then you get a list. And you have to pick the one that doesn't belong That's the part that actually makes a difference..
Easier said than done, but still worth knowing.
Here's the thing — polycythemia isn't a single disease. But exams love to test the mimics. The near-misses. The "wait, does this cause it or not?It's a lab finding. And the list of things that don't cause it is actually longer than the list of things that do. " conditions.
Let's walk through it properly. No memorization tricks. Just physiology, pattern recognition, and the clinical context that makes it stick.
What Is Polycythemia, Really?
Polycythemia means an increased red cell mass. That's it. So not a diagnosis. A description.
But in practice, we split it two ways — and this distinction matters more than anything else on exam day.
Absolute polycythemia is a true increase in red cell mass. More red cells. Period. This breaks down further into primary (the bone marrow is doing it on its own) and secondary (something is telling the marrow to make more).
Relative polycythemia — also called spurious or stress polycythemia — isn't a real increase at all. The red cell mass is normal. The plasma volume dropped. Dehydration, burns, diuretic overuse, Gaisböck syndrome (hypertension + obesity + smoking). The hematocrit looks high because the denominator shrank.
Exams love relative polycythemia because it's a distractor. You see a high Hct and your brain screams "polycythemia!Day to day, or they're on furosemide 80 mg BID. " — but the patient just has cholera-level diarrhea. The red cell mass? Totally normal Small thing, real impact..
Why the Distinction Between Primary and Secondary Changes Everything
Primary polycythemia means the marrow has gone rogue. The classic — really, the only one you need to know for boards — is polycythemia vera (PV). The marrow doesn't need permission. JAK2 V617F mutation (95% of cases), exon 12 mutations (the other ~3-4%). Low or undetectable. EPO level? It just builds.
Secondary polycythemia means something is driving EPO up. And here's where it gets clinically useful: **appropriate vs. inappropriate Small thing, real impact..
Appropriate secondary polycythemia — the body should be making more red cells because tissue oxygen delivery is compromised. Worth adding: carbon monoxide poisoning (heavy smokers). Plus, high altitude. Cyanotic congenital heart disease (right-to-left shunts). Because of that, the kidney senses hypoxia → makes EPO → marrow responds. Chronic lung disease (COPD, interstitial fibrosis). Because of that, sleep apnea. Appropriate.
Honestly, this part trips people up more than it should.
Inappropriate secondary polycythemia — EPO is high, but there's no hypoxic drive. Pheochromocytoma. Androgenic steroids. Because of that, the kidney (or something else) is secreting EPO autonomously. Also, renal cell carcinoma. Hepatocellular carcinoma. Cerebellar hemangioblastoma. Uterine fibroids (rare but tested). Think about it: testosterone therapy — especially in older men or transmasculine patients on high-dose T. Blood doping (recombinant EPO, transfusions).
That's the framework. Everything else flows from it.
Conditions That Cause Polycythemia — The Actual List
Let's be exhaustive, because "which of the following would NOT lead to polycythemia" means you need to recognize the ones that do Less friction, more output..
Primary
- Polycythemia vera (JAK2 mutation)
Secondary — Appropriate (Hypoxic Drive)
- High altitude residence (> 10,000 ft chronic exposure)
- COPD — especially "blue bloaters" with chronic hypoxemia
- Interstitial lung disease
- Cyanotic congenital heart disease (Tetralogy of Fallot, Eisenmenger syndrome)
- Obstructive sleep apnea (nocturnal hypoxemia)
- Chronic carbon monoxide exposure (heavy smokers — CO binds Hb with 250x affinity, functional anemia)
- High-affinity hemoglobin variants (rare, genetic — left-shifted O2 dissociation curve, tissue hypoxia despite normal PaO2)
- 2,3-BPG deficiency (same mechanism)
Secondary — Inappropriate (EPO Overproduction Without Hypoxia)
- Renal cell carcinoma (classic — EPO-secreting tumor)
- Hepatocellular carcinoma
- Cerebellar hemangioblastoma (von Hippel-Lindau association)
- Pheochromocytoma
- Uterine leiomyomas / fibroids
- Renal cysts, hydronephrosis, renal artery stenosis (renal ischemia → EPO)
- Testosterone / androgen therapy (stimulates EPO production + marrow sensitivity)
- Exogenous EPO administration (doping, or therapeutic in CKD — but therapeutic targets normal Hct, not polycythemia)
- Post-renal transplant (native kidneys often keep making EPO)
Relative (Spurious) — Not True Polycythemia But Looks Like It
- Severe dehydration (volume depletion)
- Burns
- Diuretic overuse
- Gaisböck syndrome (hypertension + obesity + smoking + stress → plasma volume contraction)
- Third-spacing (sepsis, pancreatitis — though these often dilute Hct later)
That's the universe. If it's not on this list — or mechanistically identical to something on this list — it doesn't cause polycythemia Most people skip this — try not to..
What Does NOT Cause Polycythemia — The Exam Distractors
Now the real question. Here are the conditions that show up in answer choices specifically because they sound like they should cause it, or they're associated with hematologic abnormalities, but they don't.
Iron Deficiency Anemia
This is the most common "not polycythemia" distractor. Iron deficiency causes microcytic hypochromic anemia. Low Hb, low Hct, low MCV, low ferritin, high TIBC, high transferrin saturation. The marrow wants to make red cells — it's screaming for iron — but it can't. You get thrombocytosis sometimes (reactive), but never polycythemia.
If a PV patient develops iron deficiency (from phlebotomy, GI bleeding), their Hct can normalize — masking the polycythemia. This is called "masked polycythemia vera."
Diagnostic Evaluation: From Suspicion to Confirmation
When a clinician encounters an elevated hematocrit or hemoglobin, the first step is to verify that the finding is genuine polycythemia and not an artifact of plasma volume loss. A complete blood count with red‑cell indices, peripheral smear, and a plasma volume assessment (e.g., capillary hematocrit or plasma protein concentration) helps distinguish true erythrocytosis from relative concentration. If the anemia is genuine, the next tier of testing includes:
- Serum erythropoietin (EPO) – markedly low in polycythemia vera (PV) and elevated in secondary forms.
- JAK2 V617F mutation – present in >95 % of primary PV cases; its detection provides a rapid, highly specific marker.
- Calreticulin (CALR) and MPL mutations – alternative driver mutations in PV‑negative myeloproliferative neoplasms.
- Bone‑marrow examination – hypercellular marrow with megakaryocytic proliferation and erythroid hyperplasia, absent in secondary etiologies.
These investigations not only confirm the diagnosis but also stratify patients into “true” PV versus secondary polycythemia, guiding therapeutic decisions No workaround needed..
Management Principles: Balancing Hemorrhage and Thrombosis
Therapeutic goals revolve around reducing blood viscosity, preventing major thrombotic events, and mitigating disease‑specific complications. The cornerstone of PV treatment includes:
- Phlebotomy – performed to maintain hematocrit < 45 % in most adults. Serial venesections (typically 450–500 mL) are scheduled according to baseline Hct and symptom burden.
- Low‑dose aspirin – recommended for most patients to inhibit platelet aggregation and attenuate microvascular thrombosis.
- Cytoreductive agents – reserved for high‑risk individuals (age > 60 years, prior thrombosis, leukocytosis). Hydroxyurea, interferon‑α, or ruxolitinib (JAK inhibitor) are employed based on prior exposure, comorbidities, and side‑effect tolerance.
In secondary polycythemia, the underlying driver must be addressed: correction of hypoxia (e.g.Think about it: , supplemental oxygen, smoking cessation), surgical removal of an EPO‑secreting tumor, or adjustment of offending medications. When dehydration underlies apparent erythrocytosis, aggressive fluid resuscitation restores plasma volume and normalizes Hct Simple, but easy to overlook. Simple as that..
Complications and Long‑Term Monitoring
Patients with PV remain at risk for cardiovascular events, myelofibrotic transformation, and acute leukemia. Surveillance strategies include:
- Annual physical examination with focus on splenomegaly and constitutional symptoms.
- Periodic CBC to monitor for rising Hct, leukocytosis, or cytopenias secondary to treatment.
- Imaging – ultrasound of the spleen when enlargement progresses, or MRI/CT when malignancy is suspected.
- Molecular profiling – repeat testing for additional mutations that may herald disease evolution.
Early detection of fibrotic change or leukemic progression enables timely intervention, often with ruxolitinib or allogeneic stem‑cell transplantation in refractory cases That's the part that actually makes a difference..
Special Populations and Emerging Therapies
Pregnant women with PV present a unique challenge: phlebotomy is contraindicated, yet uncontrolled erythrocytosis heightens maternal and fetal complications. Low‑dose aspirin combined with therapeutic phlebotomy performed postpartum has shown efficacy. In pediatric PV, interferon‑α offers a disease‑modifying option with fewer long‑term toxicities than hydroxyurea It's one of those things that adds up..
Recent advances in JAK‑targeted therapy have expanded the therapeutic armamentarium. On the flip side, ruxolitinib, approved for PV after hydroxyurea failure, reduces spleen volume and symptom burden while allowing sustained phlebotomy‑free remission in a subset of patients. Ongoing trials are evaluating next‑generation JAK inhibitors and novel CALR‑directed strategies, heralding a future where molecular insights drive personalized management Which is the point..
Conclusion
Polycythemia is not a monolithic disease; it encompasses a spectrum ranging from the clonal, driver‑mutation‑positive polycythemia vera to a myriad of secondary triggers that mimic its laboratory profile. Recognizing the underlying etiology — whether a JAK2‑driven myeloproliferative neoplasm, a hypoxic stimulus, or a spurious concentration artifact — is essential for accurate diagnosis and tailored therapy. By integrating solid diagnostic work‑up, vigilant monitoring, and evidence‑based interventions, clinicians can markedly reduce the risk of thrombotic and fibrotic complications, improve quality of life, and ultimately transform polycythemia from
a once‑feared hematologic diagnosis into a manageable chronic condition with a favorable long‑term outlook.
Simply put, the care of patients with polycythemia demands a precise etiologic classification, individualized risk stratification, and a multidisciplinary approach that bridges hematology, primary care, and, where relevant, obstetrics or oncology. As our understanding of clonal architecture and microenvironmental cues deepens, the transition from generalized cytoreduction to molecularly guided therapy will continue to refine outcomes and minimize iatrogenic harm Nothing fancy..
